CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Receptos LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Receptos LLC
10835 Road to the Cure
Phone: (858) 652-5700p:858 652-5700 San Diego, CA  92121  United States Fax: (858) 587-2659f:858 587-2659
This company ceased filing statements with the SEC on 9/8/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Receptos LLC (Receptos) is a biopharmaceutical company which is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. Receptos LLC developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn’s Disease (CD). The Company is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201512/31/2014YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board, Co-Founder William H.Rastetter 67 5/1/2009 5/1/2009
President, Chief Executive Officer, Director FaheemHasnain 56 11/1/2010 11/1/2010
Co-Founder, Chief Technology Officer Marcus F.Boehm 55
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Apoptos, Inc.
RCPT

General Information
Number of Employees: 68 (As of 12/31/2014)
Outstanding Shares: 31,606,369 (As of 7/20/2015)
Shareholders: 25
Stock Exchange: NASD
Federal Tax Id: 264190792
Fax Number: (858) 587-2659


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023